Navigation Links
Celladon Corporation Announces Oral Presentation at American Heart Association of Long Term Follow-Up Results from the MYDICAR CUPID 1 Trial in Advanced Heart Failure
Date:11/18/2013

SAN DIEGO, Nov. 18, 2013 /PRNewswire/ -- Celladon Corporation, a clinical-stage biotechnology company focused on developing novel therapies by applying its leadership position in the field of SERCA enzymes, today announced that on behalf of the CUPID 1 Trial investigators, Dr. Barry H. Greenberg will present the full three year long-term follow up results from Phase 2a of the CUPID 1 trial in an oral presentation at the American Heart Association Scientific Sessions 2013 Conference held in Dallas, Texas. Phase 2a of the CUPID 1 trial investigated Celladon's product candidate MYDICAR in three dose groups for the treatment of advanced heart failure.

The details of the presentation are as follows:

  • Session Type: Abstract Oral Session
  • Session Title: 502. Novel Cell, Tissue Engineering, and Gene Based Strategies For Heart Failure
  • Abstract Title: Long Term Follow-up Of Patients With Advanced Heart Failure Following A Single Intracoronary Infusion Of AAV1/SERCA2a
  • Presentation Date/Time: 11/19/2013 9:00:00 AM Central time
  • Presenter: Barry H. Greenberg M.D., FACC, Director, Advanced Heart Failure Treatment Program; Professor of Medicine, University of California, San Diego

Dr. Greenberg stated, "The results of the long-term follow up of the CUPID patients at 36 months are a major step forward in the development of a promising new therapy for treating heart failure. Evidence of continued reduction in events with high dose MYDICAR compared to placebo extending out to 36 months and the persistence of transgene expression in the heart are very encouraging findings that support the possibility that MYDICAR has an important impact on the clinical course of heart failure patients."

"The durability of treatment effect and lack of safety concerns ob
'/>"/>

SOURCE Celladon Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Celladon Corporation Named a 2012 Fierce 15 Company by FierceBiotech
2. Celladon Corporation To Present at BioCentury Future Leaders in the Biotech Industry Conference
3. Celladon Corporation and SIRO Clinpharm Announce Presentation at "Statisticians in the Pharmaceutical Industry International Conference"
4. Celladon Corporation Selected as Winner of Red Herrings "Top 100 North America Tech Startup"
5. Celladon Corporation Announces Pre-clinical Study Demonstrating Inhalable MYDICAR Reverses Pulmonary Arterial Hypertension (PAH)
6. Celladon Corporation Announces Appointment of Gregg Alton and Graham Cooper to its Board of Directors
7. Celladon Corporation Announces Publication of Long Term Follow-Up Results from the MYDICAR CUPID 1 Trial in Advanced Heart Failure
8. China Cord Blood Corporation to Report Second Quarter and First Half of Fiscal 2012 Financial Results
9. Kensey Nash Corporation Announces Achievement of $6 Million Milestone From Spectranetics Corporation
10. China Cord Blood Corporation Announces Results of 2011 Annual General Meeting
11. Neogen Corporation Announces 2nd Quarter Results Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... Lewisville, TX (PRWEB) September 18, 2014 ... PVC-C, a FM-4910 listed material, to stay competitive ... industries. These high-performance materials ultimately impact product ... company’s President and owner. , Established in 1980 ... held strong as many fabricators have left the ...
(Date:9/18/2014)... DIEGO , Sept. 18, 2014  MEI Pharma, Inc. ... the clinical development of novel therapies for cancer, announced today ... Executive Officer, will present at BioCentury,s NewsMakers in the ... 8:30 a.m. Eastern time from the Millennium Broadway Hotel & ... live webcast of the presentation can be accessed at ...
(Date:9/18/2014)... SEATTLE , Sept. 18, 2014 /PRNewswire/ - Oncothyreon ... pricing of previously announced concurrent but separate underwritten offerings ... price to the public of $2.00 per share, for ... of its Series A Convertible Preferred Stock at a ... expected gross proceeds of $20 million. Each share of ...
(Date:9/18/2014)... Sept. 18, 2014   Sigma-Aldrich Corporation ... has entered into a new gene editing partnership ... Vector Core. Under the partnership, Sigma-Aldrich will provide ... design consultation, and dedicated gene editing bioinformaticians. ... editing-based research at the U-M Medical School. One ...
Breaking Biology Technology:Leatherwood Plastics Selects Vycom’s Flametec PVC-C Material to Stay Competitive in Semiconductor and Lab Equipment Industries 2MEI Pharma To Present At BioCentury's NewsMakers Conference 2MEI Pharma To Present At BioCentury's NewsMakers Conference 3Oncothyreon Prices $40 Million Concurrent Public Offerings of Common Stock and Preferred Stock 2Oncothyreon Prices $40 Million Concurrent Public Offerings of Common Stock and Preferred Stock 3Sigma-Aldrich, University of Michigan Medical School Establish CRISPR Core Lab Partnership 2Sigma-Aldrich, University of Michigan Medical School Establish CRISPR Core Lab Partnership 3Sigma-Aldrich, University of Michigan Medical School Establish CRISPR Core Lab Partnership 4
... BioMS Medical Corp (TSX: MS), a leading developer in the treatment of ... will present at BioFinance 2009 in Toronto., WHEN: ... Marriott Eaton Centre Hotel (Trinity V room), ... Toronto, ON, About ...
... 24 United Therapeutics Corporation (Nasdaq: UTHR ... first quarter financial results before market open on Friday, ... on Friday, May 1, 2009, at 9:00 a.m. Eastern ... with international callers dialing 719-325-4795. A rebroadcast of ...
... 24 LyondellBasell Industries today announced that LyondellBasell ... Lyondell Chemical Company,s reorganization filing under Chapter 11 ... European holding company against claims by certain financial ... S.C.A. is a holding company incorporated in Luxembourg. ...
Cached Biology Technology:BioMS Medical to present at BioFinance 2009 2LyondellBasell Adds Holding Company to Chapter 11 Protection 2
(Date:9/18/2014)... the International Space Station ever starts a "frequent flyers" ... status. Recently the orbiting laboratory has hosted increasing numbers ... returned from the space station in April, and another ... third experiment is planned to launch in December. , ... around the world-- and in space. Model organisms can ...
(Date:9/18/2014)... of Americans to undertake jaunts into the countryside each year ... within a century, according to new research. , Climate change ... United States as summer temperatures linger later into the year, ... and Biogeography . For instance, the paper birch a ... Hampshire could change color one to three weeks later ...
(Date:9/18/2014)... stored in DNA, tiny strands of nucleic acid that ... express this genetic data, our DNA is copied into ... that perform tasks in our cells. , Several ... molecule. Unlike all other known RNAs, this molecule is ... are abundant, little has been known about how they ...
Breaking Biology News(10 mins):Buzzing with activity: Fruit flies orbit Earth for science 2Buzzing with activity: Fruit flies orbit Earth for science 3Buzzing with activity: Fruit flies orbit Earth for science 4Fall foliage season may be later, but longer on warmer Earth 2Fall foliage season may be later, but longer on warmer Earth 3Fall foliage season may be later, but longer on warmer Earth 4Scientists find how mysterious 'circular RNA' is formed, claim muscular dystrophy link 2
... , April 27 Southwest Bancorp, Inc. (Nasdaq: OKSB ), ... shares of common stock at a price to the public of $12.50 ... offering was increased from the previously announced offering size of approximately $40 ... . , , , ...
... China , April 27 /PRNewswire-Asia-FirstCall/ ... or "the Company"), the,Xianyang-based manufacturer of a leading ... ("Xin Aoxing"), and other pharmaceutical,products, announced today it ... and Drug Administration ("SFDA") for marketing Xin Aoxing,Oleanolic ...
... Katie Michaels , star of Barely Legal 100 and other fine ... returning to Phoenix to attend game seven of the NHL playoffs between ... , , ... , "After finishing ...
Cached Biology News:Southwest Bancorp, Inc. Announces Pricing of $50 Million Underwritten Public Offering of Common Shares 2Southwest Bancorp, Inc. Announces Pricing of $50 Million Underwritten Public Offering of Common Shares 3Biostar Pharmaceuticals, Inc. Receives New Advertising Approval from Shaanxi SFDA for Marketing Xin Aoxing Capsule 2Biostar Pharmaceuticals, Inc. Receives New Advertising Approval from Shaanxi SFDA for Marketing Xin Aoxing Capsule 3Adult Star Katie Michaels Attending NHL Game 7 Red Wings vs. Coyotes 2
... 8-iso PGE2 is one of several isoprostanes ... is a potent renal vasoconstrictor in the rat. ... with IC50 values of 0.5 and 5 µM, ... the rat at a concentration of 4 mg/kg/min, ...
... The Centra-CL5R multi-purpose centrifuge offers ... a large assortment of rotor options, ... of laboratory applications., Maximum Versatility , ... 21,000 xg) angle rotors or high-volume (4 ...
...
... The Turn & Cast submarine gel systems used gasketed ... the gel in the tank. Turn it back and ... For added convenience, each Turn & Cast tray is ... near the edge of the tray and one in ...
Biology Products: